Viva-Thera nominates HIV drug candidate after seven months using XtalPi's AI

Founder Qingshan Fu built on years of HIV structural research; the candidate and the seven-month timeline remain company-reported.

By · Published · Updated

Primary source: XtalPi company announcement via Financial Times Markets

Why it matters

Fu's published MPER research gives Viva-Thera a biological starting point for XtalPi's AI-assisted discovery. The seven-month candidate selection tests that combination as a development model, while efficacy and safety remain to be established.

A researcher's gloved hands work on molecular models and computer simulations in a high-tech drug discovery lab.

Qingshan Fu founded Viva-Thera around a part of HIV he had studied for years. On September 22nd, Viva-Thera and XtalPi said that work had produced a preclinical small-molecule drug candidate in seven months, using XtalPi's AI design tools and automated laboratory. The milestone is a candidate selected for further development, not a medicine tested in people.…

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Reader comments

Conversation for this story loads after sign-in.